---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-020566"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:54:30.069348+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial

## Summary
- Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.
- Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.
- Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.
- Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance.

## SEC filing metadata
- accession: 0001213900-24-020566
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/0001213900-24-020566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/ea0201282-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-020566
- JSON: https://secwatch.observer/filing/0001213900-24-020566.json
- Plain text: https://secwatch.observer/filing/0001213900-24-020566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.